Last reviewed · How we verify
BF2.649 add on Modafinil
BF2.649 is a histamine H3 receptor antagonist that enhances wakefulness and cognitive function when combined with modafinil's dopamine/norepinephrine reuptake inhibition.
BF2.649 is a histamine H3 receptor antagonist that enhances wakefulness and cognitive function when combined with modafinil's dopamine/norepinephrine reuptake inhibition. Used for Excessive daytime sleepiness in narcolepsy (as add-on to modafinil), Cognitive impairment and fatigue in neurological conditions.
At a glance
| Generic name | BF2.649 add on Modafinil |
|---|---|
| Also known as | Pitolisant, Modiodal |
| Sponsor | Bioprojet |
| Drug class | Histamine H3 receptor antagonist |
| Target | Histamine H3 receptor (H3R) |
| Modality | Small molecule |
| Therapeutic area | Neurology / Sleep Medicine |
| Phase | Phase 3 |
Mechanism of action
BF2.649 blocks histamine H3 receptors, which are inhibitory autoreceptors on histaminergic neurons in the brain. This blockade increases histamine release and promotes wakefulness and alertness. When used as an add-on to modafinil, it provides complementary mechanisms to enhance arousal, vigilance, and cognitive performance through multiple neurotransmitter systems.
Approved indications
- Excessive daytime sleepiness in narcolepsy (as add-on to modafinil)
- Cognitive impairment and fatigue in neurological conditions
Common side effects
- Insomnia
- Headache
- Anxiety
- Tremor
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |